{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:31:50Z","timestamp":1774276310840,"version":"3.50.1"},"reference-count":25,"publisher":"Media Sphere Publishing House","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. nevrol. psikhiatr. im. S.S. Korsakova"],"published-print":{"date-parts":[[2017]]},"DOI":"10.17116\/jnevro2017117111140-145","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T09:48:12Z","timestamp":1513849692000},"page":"140","source":"Crossref","is-referenced-by-count":3,"title":["Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis"],"prefix":"10.17116","volume":"117","author":[{"given":"T. E.","family":"Shmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro2017117111140-145-1","unstructured":"Rieckman P. Inflamation and neurodegenaration: the role of these dual players in MS. Therapeutic strategies in MS: from neuroprotection to long term efficacy. 2004;5-10."},{"key":"key-10.17116\/jnevro2017117111140-145-2","unstructured":"Shmidt TE, Yakhno NN. Rasseyannyi skleroz. M.: MED press-inform; 2016. (In Russ.)"},{"key":"key-10.17116\/jnevro2017117111140-145-3","unstructured":"Zhuchenko TD, Shmidt TE. Kopakson \u2014 novoe sredstvo dlya lecheniya rasseyannogo skleroza. Vestn prakt nevr. 1998;4;194-196. (In Russ.)"},{"key":"key-10.17116\/jnevro2017117111140-145-4","doi-asserted-by":"crossref","unstructured":"Burks J. Interferon beta-1b in MS. Expert Review of Neurotherapeutics. 2005;5(2):153-164.","DOI":"10.1586\/14737175.5.2.153"},{"key":"key-10.17116\/jnevro2017117111140-145-5","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-011-0218-7"},{"key":"key-10.17116\/jnevro2017117111140-145-6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0486-3"},{"key":"key-10.17116\/jnevro2017117111140-145-7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-1007-3"},{"key":"key-10.17116\/jnevro2017117111140-145-8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"key-10.17116\/jnevro2017117111140-145-9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0909494"},{"key":"key-10.17116\/jnevro2017117111140-145-10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03110.x"},{"key":"key-10.17116\/jnevro2017117111140-145-11","doi-asserted-by":"publisher","DOI":"10.21518\/2079-701X-2015-18-74-79"},{"key":"key-10.17116\/jnevro2017117111140-145-12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0348-9"},{"key":"key-10.17116\/jnevro2017117111140-145-13","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201611610268-72"},{"key":"key-10.17116\/jnevro2017117111140-145-14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114287"},{"key":"key-10.17116\/jnevro2017117111140-145-15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-6954-7"},{"key":"key-10.17116\/jnevro2017117111140-145-16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7412-x"},{"key":"key-10.17116\/jnevro2017117111140-145-17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206328"},{"key":"key-10.17116\/jnevro2017117111140-145-18","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.148"},{"key":"key-10.17116\/jnevro2017117111140-145-19","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516649037"},{"key":"key-10.17116\/jnevro2017117111140-145-20","unstructured":"Couto E, Hamidi V, Ringerike T, Odgaard-Jensen J, Harboe I, Klemp M. Medicines used for Multiple Sclerosis \u2014 A Health Technology. Norwegian Institute of Public Health. Oslo. 2016"},{"key":"key-10.17116\/jnevro2017117111140-145-21","unstructured":"Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza J. 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. In Clinical Measures and Impact on Patient-Reported Outcomes of Delayed-release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients After Suboptimal Response to Glatiramer Acetate: Analysis of the 12-Month RESPOND Study. London, UK: 14-17 September, 2016."},{"key":"key-10.17116\/jnevro2017117111140-145-22","doi-asserted-by":"crossref","unstructured":"Spelman T, Kalincik T, Trojano M, Grand'Maison F, Izquierdo G, Havrdova E, Horakova D, Lugaresi A, Duquette P, Grammond P, Hupperts R, Lechner-Scott J, Granella F, Petersen T, Terzi M, Pucci E, Sola P, Van Pesch V, Iuliano G, Oreja-Guevara C, Boz C, Bergamaschi R, Slee M, Butzkueven H, on behalf of the MSBase Investigators 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide. London, UK: [s.n.]. 14\u201417 September, 2016","DOI":"10.1212\/WNL.88.16_supplement.P6.372"},{"key":"key-10.17116\/jnevro2017117111140-145-23","doi-asserted-by":"crossref","unstructured":"Nicholas J, Boster A, Wu N. Comparative Effectiveness of Delayed-Release Dimethyl Fumarate versus Fingolimod and Teriflunomide for Risk of Relapse. P6.375. Presented at American Academy of Neurology. 2017 \u2014 69th Annual Meeting I April 22-28, 2017 I Boston, MA.","DOI":"10.1212\/WNL.88.16_supplement.P6.375"},{"key":"key-10.17116\/jnevro2017117111140-145-24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.06.001"},{"key":"key-10.17116\/jnevro2017117111140-145-25","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20171171197-102"}],"container-title":["Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T23:24:42Z","timestamp":1719703482000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2017\/11\/downloads\/ru\/1199772982017111140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"alternative-id":["jnevro2017117111140-145"],"URL":"https:\/\/doi.org\/10.17116\/jnevro2017117111140-145","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}